26 July, 2017
However, the top line needs to show sustained improvement. Coca Cola Femsa S.A.B.de C.V. Equities research analysts forecast that Coca Cola Femsa S.A.B.de C.V. will post $4.05 EPS for the current year.
Several other research firms also recently commented on KO. Out of the 8 covering sell-side analysts giving share ratings for Bemis Company, Inc. Finally, Stifel Nicolaus reaffirmed a "hold" rating and issued a $45.00 price target on shares of Coca-Cola Company (The) in a report on Friday, July 14th. They noted that the move was a valuation call. Five brokerages rating the company a strong buy, seven brokerages rating the company a buy, twelve brokerages rating the company a hold, one brokerage rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $47.95.
The Monterrey-based company controls the world's biggest Coke bottler, Coca-Cola Femsa. Investors may also be paying close concentration to some simple moving average indicators on shares of Baker Hughes, a GE company (BHGE). 6 analysts have put a Hold rating on the stock, and 1 are giving a Sell recommendation. The stock of Coca-Cola European Partners plc Ordinary Shares (NYSE:CCE) earned "Buy" rating by UBS on Wednesday, January 11. Its down 4.05% from 2.01M shares previously. The firm's 50 day moving average price is $41.09 and its 200-day moving average price is $37.85. Coca-Cola Company has a 1-year low of $39.88 and a 1-year high of $46.06.
Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) last released its earnings results on Tuesday, May 9th. The company has market cap of $532.28 million. This second quarter marks Quincey's first earnings report as CEO of Coca-Cola. Creative Planning now owns 3,696 shares of the company's stock worth $139,000 after buying an additional 1,402 shares in the last quarter. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & worldwide trademark & copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/07/25/coca-cola-femsa-s-a-b-de-c-v-kof-lifted-to-buy-at-zacks-investment-research-updated-updated.html.
The firm also recently declared a quarterly dividend, which will be paid on Monday, October 2nd. The ex-dividend date was set for Thursday the 18th of May 2017. This represents a $1.00 annualized dividend and a dividend yield of 0.42%. Coca-Cola Company (The)'s dividend payout ratio (DPR) is presently 103.50%. The shares were sold at an average price of $45.20, for a total transaction of $1,323,546.40.
As the earnings date approaches, we can see that insider ownership is now 0.40% shares, and institutional ownership is at 65.20% for The Coca-Cola Company (NYSE:KO) stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. ABN Amro reissued a "sell" rating on shares of Coca-Cola European Partners PLC in a report on Friday, April 28th. Going toward to the 50-day, we can see that shares are now trading -7.83% off of that figure. The disclosure for this sale can be found here. Following the completion of the sale, the insider now directly owns 780,258 shares in the company, valued at $35,111,610. Leavell Investment Management Inc. acquired a new position in Coca-Cola Bottling Co. Bank of Montreal Can now owns 57,828 shares of the company's stock valued at $4,147,000 after buying an additional 42,751 shares during the last quarter.
Coca-Cola's net revenues for the quarter fell 16 percent to $9.7 billion, impacted by the company's ongoing efforts to refranchise its bottling territories. The company maintains price to book ratio of 1.21. More interesting news about The Coca-Cola Co (NYSE:KO) were released by: Nasdaq.com and their article: "Franklin Street Advisors Inc Buys Coca-Cola Co, JPMorgan Chase, Cisco Systems ..." published on July 14, 2017 as well as Nasdaq.com's news article titled: "Daiwa SB Investments Ltd. Buys Coca-Cola Co, NetEase Inc, JD". Looking at stock performance for the past six months, shares are 40.38%.
Coca-Cola Enterprises, Inc (CCE) markets, produces and distributes nonalcoholic beverages. The Company's autologous cell therapy products include Carticel, which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns.
